Favorable CGM metrics do not exclude SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: an educational case report with narrative review of literature. (PubMed, Endocr J) - Sep 17, 2026 - "We report an educational case of a 45-year-old man with type 1 diabetes (T1D) receiving ipragliflozin who developed severe euDKA precipitated by COVID-19...Therefore, clinicians must prioritize symptom-based sick-day rules over "normal" glucose numbers to prevent false reassurance from clinically acceptable CGM metrics. This case underscores the inherent limitations of glucose-centric monitoring and the necessity of multifaceted patient education."
Journal • Diabetes • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Type 1 Diabetes Mellitus
|
|
Hirotaka Shibata; Miyuki Iwamoto; Shuji Hidaka; Takamasa Iwamoto
|